Temozolomide

For research use only.

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856,TMZ

98 publications

Temozolomide Chemical Structure

CAS No. 85622-93-1

Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 79 In stock
USD 70 In stock
USD 170 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Temozolomide has been cited by 98 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide (CCRG81045, NSC 362856, TMZ) is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells. Temozolomide induces apoptosis and exhibits antitumor activity.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfEcJNRPDhiaB?= M3nGfmlEPTB;MUO5MlIx6oDLwsJihKk2Njl3IN88US=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
KellyCis83 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUm0PEBp NIf6OYhKSzVyPUK1NU4xOOLCidMx5qCKOTVwN{Wg{txO NUTLTWpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
SK-N-AS NXLCSWN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zYOlQ5KGh? M{HVWGlEPTB;MkK3Mlcx6oDLwsJihKkzOi5zNTFOwG0> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
SK-N-ASCis24 NIPJfGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:0PEBp NF\ES3VKSzVyPUS4NE43OOLCidMx5qCKOTBzLkG1JO69VQ>? NWS4e4t[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OlAzQDJpPkK1PVYxOjh{PD;hQi=>
CHP-212 M4XNd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXFO49SPDhiaB?= NV\ZS3Z4UUN3ME23Mlk46oDLwsJihKkxNjZ7IN88US=> M{Dud|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[wNlgzLz5{NUm2NFI5OjxxYU6=
CHP-212Cis100 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjabXc1QCCq MV3JR|UxRTlwNUZihKnDueLCiUCuPFgh|ryP MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4MEK4Nkc,OjV7NkCyPFI9N2F-
U87  NEjFZ2VHfW6ldHnvckBCe3OjeR?= NFfmdmQyODBizszN MYiyOE04OiCq NFvDcHBqdmS3Y3XzJGRkWjFiZYjwdoV{e2mxbh?= M3\xeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEC4PFY5Lz5{NUiwPFg3QDxxYU6=
LN229 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTBS4hKOC13MDFOwG0> MUXJR|UxRTF4IN88US=> NFjCPHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe1NFI4Oyd-MkW3OVAzPzN:L3G+
TR-LN229 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MViwMVUxKM7:TR?= NV\4XllrUUN3ME23O{DPxE1? NWTzdHlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3OVAzPzNpPkK1O|UxOjd|PD;hQi=>
U87  NHTsc2tCeG:ydH;zbZMhSXO|YYm= M{TEUVDjiJN{MEFihKnDvU1? MYWyOEBp Mn\q[Y5p[W6lZYOgR3EhcW6mdXPl[EBieG:ydH;zbZM> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MU[2PEc,OjV4OEG2Olg9N2F-
U251MG MX7BdI9xfG:|aYOgRZN{[Xl? M4\uTVExOMLizszN NHPtWoc1QCCq MoDqVGJU Mm\RbY5lfWOnczDhdI9xfG:|aYO= NGXOfXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NFQ3PCd-MkW2PFA1PjR:L3G+
U87MG M2PIXmFxd3C2b4Ppd{BCe3OjeR?= Mn\FNVAxyqEQvF2= MWO0PEBp M3q5ZnBDWw>? M1zEbolv\HWlZYOgZZBweHSxc3nz NGCwOnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[4NFQ3PCd-MkW2PFA1PjR:L3G+
U87 MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofpOVAuOzVyIN88US=> MYS0POKhcMLi M2LGTYlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 Mof0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
U118  MnW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[1NE0{PTBizszN NET6Rmo1QMLiaNMg NIrOUm1qdmirYnn0d{Bk\WyuIHfyc5d1cCC|bHnnbJRtgQ>? NHvpUHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OFIzOyd-MkW1OVQzOjN:L3G+
U87 M{n2XWZ2dmO2aX;uJGF{e2G7 Mk\nNlUxNzN3MDFOwG0> M3;LUVQ5yqCqwrC= MnHZ[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm NHvZUHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1OFIzOyd-MkW1OVQzOjN:L3G+
U118  NEPF[HZHfW6ldHnvckBCe3OjeR?= MmjpNlUxNzN3MDFOwG0> MoroOFjDqGkEoB?= NVfOXnM1\W6qYX7j[ZMhXE2[LXnu[JVk\WRicD3QT2MueGGwIHTlZ5Jm[XOn MmrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3NUSyNlMoRjJ3NUW0NlI{RC:jPh?=
U87 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSyOVAwOzVyIN88US=> MknXOFjDqGkEoB?= NH;RcYVqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS|IwVcLiY3;0doVifGWmIIfpeIghXE2[ M3\ySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW0NlI{Lz5{NUW1OFIzOzxxYU6=
A375 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[0POKhcMLi NW\zNWFDUUN3ME2yOlUh|ryP MlfiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
A2058 M2W3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DDWFQ5yqCqwrC= NUDvOppZUUN3ME2xNkDPxE1? MmT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3MkS1OVIoRjJ3NUK0OVUzRC:jPh?=
M238 NX\LcGp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfR[Wp5PDkEoHlCpC=> NWTnOIU1UUN3ME20NEDPxE1? NGXmSHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWyOFU2Oid-MkW1NlQ2PTJ:L3G+
M249 NYjXc5ZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTUfpNPPDkEoHlCpC=> NITXSotKSzVyPUK1OEDPxE1? MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{NEW1Nkc,OjV3MkS1OVI9N2F-
M21 NUXXUW9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HY[VQ5yqCqwrC= NWLIOm82UUN3ME2yNlEh|ryP MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV{NEW1Nkc,OjV3MkS1OVI9N2F-
U251 MWfDfZRwfG:6aYT5JGF{e2G7 Ml:wNlAh|ryPwrC= MUe0POKhcMLi NXr3R4Q4emWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> Mm\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2M{SzPFEoRjJ3NEO0N|gyRC:jPh?=
LN229 NYPYZoVDS3m2b4TvfIl1gSCDc4PhfS=> MYqyNEDPxE4EoB?= M{TkSVQ5yqCqwrC= MkDWdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= NUTESXdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|Q{QDFpPkK1OFM1OzhzPD;hQi=>
U373MG-LUC M1uzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUe0N|FyPzJiaB?= NFznNIFKSzVyPk[wNEDPxE1? NWi5[G5ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0N|E6PTNpPkK1OFMyQTV|PD;hQi=>
U87  NFX4S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXtNlUuOjByIN88US=> NVLZNmJIPDkEoHlCpC=> Ml7RbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MEC3OFUoRjJ3NECwO|Q2RC:jPh?=
U251 NYrKeVhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrpeoczPS1{MECg{txO MXq0POKhcMLi Mnm4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEnlTlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSwNFc1PSd-MkW0NFA4PDV:L3G+
U251 M2DW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\JVWoyODBvNECwJO69VQ>? NVHzW4JpPzJxOU[gbC=> M2TDTpRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MknxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|N{WyO|EoRjJ3M{e1NlcyRC:jPh?=
U373 NUSyS21xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSwNVAxNTRyMDFOwG0> NWfRR5VYPzJxOU[gbC=> M{PYeJRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= NW\xTJdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzO|UzPzFpPkK1N|c2OjdzPD;hQi=>
U343 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH76NpcyODBvNECwJO69VQ>? Mn3QO|IwQTZiaB?= NXiyZmZQfGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg NHTvTmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3OVI4OSd-MkWzO|UzPzF:L3G+
U87MG-luc2 Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki2NVAxNTRyMDFOwG0> M1rHS|czNzl4IHi= MYP0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NIHMVnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUO3OVI4OSd-MkWzO|UzPzF:L3G+
U87 NIjNV3hHfW6ldHnvckBCe3OjeR?= MnLhNlAxKM7:TR?= M1nsWVQ5KGh? NEXocXNqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w NV\SVmRtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
U251 NVzLOIxXTnWwY4Tpc44hSXO|YYm= M1LKRlIxOCEQvF2= NX;a[mRTPDhiaB?= M4P1VIlv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? M1jIO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O|IyLz5{NUOzO|czOTxxYU6=
A172 MlvzSpVv[3Srb36gRZN{[Xl? MlTDNlAxKM7:TR?= MVK0PEBp M1fWS4lv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MoDHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{e3NlEoRjJ3M{O3O|IyRC:jPh?=
U251 MnLvSpVv[3Srb36gRZN{[Xl? MmSxNlAxKM7:TR?= M3vCdVQ5KGh? NGLDUW1qdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{ MoP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|M{e3NlEoRjJ3M{O3O|IyRC:jPh?=
A172 MmrsSpVv[3Srb36gRZN{[Xl? MWOyNFAh|ryP NXTIXWI6PDhiaB?= MlzubY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGJTS0FzLDDCVmNCOixiUlHEOVEh[W6mIF\BUmNFOg>? NUD0blVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
U87 M1ruVmZ2dmO2aX;uJGF{e2G7 M{nLc|IxOCEQvF2= M2T1TFI1Nzd{L{GyNEBp MWjpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> NVHqb4E3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
U251 MkHkSpVv[3Srb36gRZN{[Xl? NFXvfFQzODBizszN M3TtU|I1Nzd{L{GyNEBp NEfZNpBqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? M3HzbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{O3O|IyLz5{NUOzO|czOTxxYU6=
A172 Mmq1SpVv[3Srb36gRZN{[Xl? MWeyNFAh|ryP M1nvTFI1Nzd{L{GyNEBp NHfBTplqdmO{ZXHz[ZMh|rOKMlHYJIZw[2liZn;ycYF1cW:wIITpcYUu\GWyZX7k[Y51dHl? NUCxTVJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzN|c4OjFpPkK1N|M4PzJzPD;hQi=>
SNB19V NEP2[2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fZbVch\A>? Mnv2SG1UVw>? NVjXeFJ7T0l3ME2zOU44yrFzMjFOwG0> Moi4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
SNB19M NHu0W2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETNSpo4KGR? MV\EUXNQ MXTHTVUxRTR4OT65xtE5QCEQvF2= MmLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
SNB19VR M2DBU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXZZlY4KGR? MYHEUXNQ MnzVS2k2OD1{OECuNuKyOThizszN M1W5Z|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mke3OFQyLz5{NUK3O|Q1OTxxYU6=
U373V NUDzN|NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX4cWQ4KGR? M1OzOmROW09? M3rmUmdKPTB;NkiuNOKyOzJizszN MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
U373M MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1iwUVch\A>? NYCzV|huTE2VTx?= M13jcmdKPTB;M{[4MlfDuTh4IN88US=> MonpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
U373VR NYXvSZBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\BSWxbPyCm NYnsOng4TE2VTx?= MXTHTVUxRTJ6OD64xtE{OyEQvF2= Ml;6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
U87MG NIjsVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\PdWtWPyCm NX\RRlh4TE2VTx?= MYfHTVUxRTN6LkRCtVIxKM7:TR?= Mm\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{e0OFEoRjJ3Mke3OFQyRC:jPh?=
HCT116 NFTEZ49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLsO{Bl NWmzfI1yTE2VTx?= MVrHTVUxRTV5OT65xtE{OiEQvF2= NE\SRnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q1OSd-MkWyO|c1PDF:L3G+
DLD1 NX\lW45VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfpbGM4KGR? MmKxSG1UVw>? MV7HTVUxRTVyMT60xtE6OyEQvF2= NYfkUIM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c1PDFpPkK1Nlc4PDRzPD;hQi=>
MRC5 NH3CVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3JIQ> MnnDSG1UVw>? NEfIemRIUTVyPUS0PU41yrF6IN88US=> NF2yfmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Q1OSd-MkWyO|c1PDF:L3G+
SNB19V  M4DLU2Z2dmO2aX;uJGF{e2G7 M4X0S|ExOCEQvF5CpHROYg>? MorzNE04OiCq M3XGOIlv[3KnYYPld{DPu0h{QWig[ZhxemW|c3nvckBj\XS5ZXXuJFE3KGGwZDC3NkBp MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5N{S0NUc,OjV{N{e0OFE9N2F-
T98G  MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\RN|UwOTBxMUWg{txO NFu5e|QzPMLiaB?= M1PJTYlv\HWlZYOgZ4VtdCCmZXH0bEBld3OnLXTldIVv\GWwdHz5JIFnfGW{IHPvcoNwdWm2YX70MZRmdW:8b3zvcYll\SC5aYToJG5R\TZvUFTU NYnUfpFjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOlI6PjFpPkK1NlYzQTZzPD;hQi=>
U251  NUKyOWxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO1M|ExNzF3IN88US=> MUOyOOKhcA>? MU\pcoR2[2W|IHPlcIwh\GWjdHig[I9{\S2mZYDlcoRmdnSueTDh[pRmeiClb37jc41qfGGwdD30[Y1wgm:ub33p[IUhf2m2aDDOVIU3NVCGVB?= M2O3XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mk[yPVYyLz5{NUK2Nlk3OTxxYU6=
T98G  MXXGeY5kfGmxbjDBd5NigQ>? MWmxOUDPxE1? MVmyOOKhcA>? NYjKPXNMcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz Mk\kQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{NkK5OlEoRjJ3Mk[yPVYyRC:jPh?=
U251  M1O2W2Z2dmO2aX;uJGF{e2G7 M{XMNlE2KM7:TR?= MknaNlTDqGh? M2jEV4lv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= NHPkW409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK2Nlk3OSd-MkWyOlI6PjF:L3G+
U-87 MG MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nF[FczKGh? NHjBXpVKSzVyPUCuPVMhdU4EoB?= NVHabm5[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU{OzJpPkK1NlQ2OzN{PD;hQi=>
U-118 MG NH:2N5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnUXIo2PzJiaB?= MkXqTWM2OD1zLkC1JI1OyqB? NULEZm1URGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyOFU{OzJpPkK1NlQ2OzN{PD;hQi=>
U87 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrjPWkzPCCq NVXMVGpOUUN3ME2yOlAvOzRizszNxsA> M4X0S|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUezNlM{Lz5{NUG3N|I{OzxxYU6=
U87 GSLCs MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITOOXozPCCq NXLJO|hKUUN3ME23OlYvOTFizszNxsA> NFrYXHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3N|I{Oyd-MkWxO|MzOzN:L3G+
U87MG MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L0WFczKGh? M{P0OGlEPTB;MUWuOlI2KM7:TdMg NFzO[2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC1NFkyPSd-MkWwOVA6OTV:L3G+
U251 Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGxNFAuPDByIN88US=> MXe0PEBp MnuySG1UVw>? NXfF[45FcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1nQRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO|M3Lz5{NE[yN|c{PjxxYU6=
U87 NHLLRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rsR|ExOC12MECg{txO M4TCRVQ5KGh? M1jK[GROW09? NYjMfoZYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M17xRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkKzO|M3Lz5{NE[yN|c{PjxxYU6=
MDA-MB-231-br NISyU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUKwMVExKM7:TR?= MW[0PEBp Mn3mSG1UVw>? MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MonQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N|YoRjJ2NkKzO|M3RC:jPh?=
HCC-1937 M1nmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjIXGsxNTNyMDFOwG0> NX;VZZBLPDhiaB?= NVPWW|RkTE2VTx?= Mln6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NU\INmJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2NlM4OzZpPkK0OlI{PzN4PD;hQi=>
MDA-MB-231 NVOwXYN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPlNE01OCEQvF2= M1rySlQ5KGh? M4DWbGROW09? NH7ZfGdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MlHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N|YoRjJ2NkKzO|M3RC:jPh?=
MDA-MB-468 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPxfVdzOC13MECg{txO NE\O[m41QCCq M2frO2ROW09? M1PzSYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N|Y9N2F-
T47D NVzKPXk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3Ke5gxNTFyMDFOwG0> MkDLOFghcA>? NGXJ[ZlFVVOR MX\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mle1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MkO3N|YoRjJ2NkKzO|M3RC:jPh?=
MCF7 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuwMVExODBizszN NVHySGZlPDhiaB?= MUDEUXNQ M4jXNolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ{M{ezOkc,OjR4MkO3N|Y9N2F-
Hs683 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYOwMVExODBizszN MX65OkBp NITJeHdKSzVyPUGyPE46KM7:TR?= MkTFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OUW5NFcoRjJ2NEm1PVA4RC:jPh?=
U87 NH3ScY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:wMVExODBizszN NXfYcXV[QTZiaB?= MXjJR|UxRTF6LkS1JO69VQ>? M3LVdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEm1PVA4Lz5{NES5OVkxPzxxYU6=
LNZ308 NIjLZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonvNE0yODByIN88US=> NXPON2hLQTZiaB?= M2XPcGlEPTB;M{K2Mlch|ryP NEDK[m09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OVkxPyd-MkS0PVU6ODd:L3G+
U87 MVLBdI9xfG:|aYOgRZN{[Xl? MoL5NVAxKM7:TR?= NXrveW4yPDhiaB?= M1\jN2ROW09? NYLkeJpwcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> NFP2TJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES4NVU5Pid-MkS0PFE2QDZ:L3G+
U251  M2H4V2Fxd3C2b4Ppd{BCe3OjeR?= NHP6RogyODBizszN NXLvPIxHPDhiaB?= NWfLSmpjTE2VTx?= MkDVbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= MnH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2OEG1PFYoRjJ2NEixOVg3RC:jPh?=
U251 NWTRW4pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLQeYkzPCCq M4HsbWlEPTB;OE[uNlnjiIoEsfMAjVEvPThizszN M2\TSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
U251 M{TpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf0XFExPDhiaB?= Mk\JTWM2OD15NT6zOQKBkcLz4pEJNU4xOiEQvF2= NFPpflE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOyOlk2PCd-MkSzNlY6PTR:L3G+
U251 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzJO|IhcA>? M4OwSGlEPTB;N{KuOFLjiIoEsfMAjVEvPDVizszN M3[4U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{K2PVU1Lz5{NEOyOlk2PDxxYU6=
U251 M{Tvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjW[HI6PiCq M4jBfWlEPTB;NkmuPFLjiIoEsfMAjVMvODRizszN MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN{Nkm1OEc,OjR|Mk[5OVQ9N2F-
T98G M2fzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLuNE04PTBizszN MoDGO|IwQTZiaB?= MkjQbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXX4R45WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNlQxQDBpPkK0N|I1ODhyPD;hQi=>
U251-MG MnW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nCfFAuQDByIN88US=> NXj1dYRQPzJiaB?= MoLxbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mny5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUO2N|AoRjJ2MEmzOlMxRC:jPh?=
D54-MG M1LyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH72UWcxNThyMDFOwG0> NHntdlI4OiCq Ml\KbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXjGeZVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVM3OzBpPkK0NFk{PjNyPD;hQi=>
SHG-44 M4LtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPwV3kyOC1{MECg{txO MVO5OkBp M3XhfGlEPTB;OT63N{DDuSB{LkGyJO69VQ>? MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
U373  M3LMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LYWlExNTJyMDFOwG0> NIPIVYw6PiCq M2rZ[2lEPTB;MUCuNVMhyrFiMT6wNkDPxE1? MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB4NUW2PUc,OjRyNkW1Olk9N2F-
HT-29  MoH0SpVv[3Srb36gRZN{[Xl? MWW1NFAh|ryP MofrNlQwPDhiaB?= MXrlcohidmOnczD0bIUhdGW4ZXzzJI9nKM7|LViyRXjDqA>? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB|OEC2PEc,OjRyM{iwOlg9N2F-
PC-3  NEHrTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjhXnQxNTJ3IN88US=> M{TrWFQ5KGh? M4XmRYlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDwc5RmdnSrYYTl[EBjgSCueXPvdIVv\Q>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd2NkmzOEc,OjN5NE[5N|Q9N2F-
PC-3  MUPBdI9xfG:|aYOgRZN{[Xl? Mne4NlUh|ryP NV;I[Hl6PDhiaB?= NVrY[JpCcW6mdXPld{BieG:ydH;zbZMhf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m NG\ib4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e0Olk{PCd-MkO3OFY6OzR:L3G+
T98G MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HoTlUxNTRyMDFOwG0> M{e5c|E1PCCq MVvpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mk\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUW0PVkoRjJ|N{G1OFk6RC:jPh?=
U87-MG NV7BVohPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2xNFAhyrWP M3fZPVczKGh? M1vQUIlvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
U251-MG M3y5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f0ZlExOCEEtV2= MVW3NkBp Mm\0bY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ7Nke4PEc,OjN4OU[3PFg9N2F-
LNT-229 M3zGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[zMVExOCEQvF2= NEKxS3czPCCq MUXpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1:xNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|Nk[3OlMzLz5{M{[2O|Y{OjxxYU6=
T98G NEnlfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETDcWQyOC15MECg{txO MWmyOEBp MVHpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke2N|IoRjJ|Nk[3OlMzRC:jPh?=
U87  MkGySpVv[3Srb36gRZN{[Xl? MYixNFAhyrWP NHixUIg{KGh? NYXxRXM2\WyndnH0[ZMhfGinIHzleoVteyCxZjDwR4hsOSCjbnSgdGNpczJ? M2KxTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|Nk[3OFY6Lz5{M{[2O|Q3QTxxYU6=
HCT116 NUH4OJZJTnWwY4Tpc44hSXO|YYm= MknMNVAxKML3TR?= NEHHcZY{KGh? MX;pcoR2[2W|IITo[UBEcGtzIGDoc5NxcG:{eXzheIlwdg>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ4N{S2PUc,OjN4Nke0Olk9N2F-
HCT3-6 M2jMVmZ2dmO2aX;uJGF{e2G7 NFX6fpcyODBiwsXN MXyzJIg> MmjObY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? MoriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4Nke0OlkoRjJ|Nk[3OFY6RC:jPh?=
U-87  Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjuNE01OCEQvF2= NGnDWpMyOiCm MmL6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4NEW3NlkoRjJ|NkS1O|I6RC:jPh?=
U-87  NHz6ZZRCeG:ydH;zbZMhSXO|YYm= M{X2S|AuPDBizszN Mm\wN{83KGR? MnO4bY5lfWOnczDhdI9xfG:|aYOgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NFrhU2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[0OVczQSd-MkO2OFU4Ojl:L3G+
U-87  M4KxZmZ2dmO2aX;uJGF{e2G7 MmPMNE01OCEQvF2= NYTTV4FtOy94IHS= M1izNIlv\HWlZYOgZZV1d3CqYXf5JIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ2NUeyPUc,OjN4NEW3Nlk9N2F-
GB-SCC010 M4j2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXweIg1KGR? M4TyWmlEPTB;MkK2JO69VQ>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
GB-SCC026 M4nFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHoOEBl NXvpUJVbUUN3ME21N{4yKM7:TR?= M4\OdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkGyO|U2Lz5{M{[xNlc2PTxxYU6=
GB-SCC028 MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:5OEBl MUPJR|UxRTF4NzFOwG0> M3;Ke|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkGyO|U2Lz5{M{[xNlc2PTxxYU6=
U87 NFf4coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;iVFFwPCCm NHjaOGJKSzVyPUS1MlIh|ryP MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzMke1OUc,OjN4MUK3OVU9N2F-
U87 stem cell NWXIWWxvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS3OEBl NHjER2ZKSzVyPU[2Mlch|ryP NUjuO4NURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVI4PTVpPkKzOlEzPzV3PD;hQi=>
TLX5 lymphoma NFzGO3ZEgXSxdH;4bYNqfHliYYPzZZk> MXLJR|UxKD1iNTFOwG0> M{LMXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd5M{mwNFgoRjd5M{mwNFg9N2F-
GM892 A MXPDfZRwfG:6aXPpeJkh[XO|YYm= NHnVeHlKSzVyIE2gO{43KM7:TR?= M4fwVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzd5M{mwNFgoRjd5M{mwNFg9N2F-
TLX5 lymphoma MXrDfZRwfG:6aXPpeJkh[XO|YYm= MojlTWM2OCB;IEWg{txO M1z5OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NEW5NFE1Lz5zMkS1PVAyPDxxYU6=
HCT116 NILKdoxEgXSxdH;4bYNqfHliYYPzZZk> MV60JIRigXN? NHm1NWxKSzVyIE2gOE4{PCEQvF2= NVXrbVlERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NFA5ODNpPkG5PFAxQDB|PD;hQi=>
SNB75 MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NU\Q[pA3OTBidV2= MV[yOEBpenN? M1LofmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU17CO|Uh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4OEWyOkc,OjJ{Nki1NlY9N2F-
C6 NIXnZ4pCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NEHOZmsyODBidV2= MW[0PEBpenN? NWHwcGJCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBz[XRiQ{[gZ4VtdHNiYYSgNVAxKHWPIHHmeIVzKDR6IHjyd{BjgSCwZYX0doFtKHKnZDDpcoNwenCxcnH0bY9vKGG|c3H5 Mn\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{Nki1NlYoRjJ{Mk[4OVI3RC:jPh?=
SF295 M3zISGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MnrwNVAhfU1? NFLoNpQzPCCqcoO= M3i4c2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1[yPVUh[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGK7IGPSRkBie3OjeR?= NIjaZmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK2PFUzPid-MkKyOlg2OjZ:L3G+
U87 NVXId2JQSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MnO3OUBl[Xm| NInBbItKSzVyIE2gOFkh|ryP MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjZyOEO4PUc,OjJ4MEizPFk9N2F-
U138MG NVHZTZVQS3m2b4TvfIlkcXS7IHHzd4F6 NIT3OGs1QCCqcoO= MYDJR|UxKD1iMk[g{txO MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB4OU[4Nkc,OjNyNkm2PFI9N2F-
C6 NX76WHZIS3m2b4TvfIlkcXS7IHHzd4F6 MWS0PEBpenN? MWXJR|UxKD1iM{Sg{txO NITydlA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C2PVY5Oid-MkOwOlk3QDJ:L3G+
A2780 NF3xXVlCdnSrdIXtc5Ih[XO|YYm= MUG1JIRigXN? MljYTWM2OCB;IEiuOUDPxE1? NGrKO3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i5OVYzOCd-MkO4PVU3OjB:L3G+
A2058 MkPxRY51cXS3bX;yJIF{e2G7 M{XOcFUh\GG7cx?= M4PNdWlEPTBiPTCzOU42KM7:TR?= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh7NU[yNEc,OjN6OUW2NlA9N2F-
SNB19 Mn\ORY51cXS3bX;yJIF{e2G7 MVW1JIRigXN? NI\EcWNKSzVyIE2gN|ch|ryP MkjzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6OUW2NlAoRjJ|OEm1OlIxRC:jPh?=
M8 MVTBdI9xfG:|aYOgZZN{[Xl? MX21NEB1dyBzMECgeW0> NVj4U4dXPDhiaILz NFPWTXpKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIF24JINmdGy|IHHzd4V{e2WmIHHzJIFxd3C2b4TpZ{9v\WO{b4TpZ{Bk\WyuczDheEA2OCC2bzCxNFAhfU1iYX\0[ZIhPDhiaILzJIJ6KEGSQz3sZYJmdGWmIHHucoV5cW5iVjDhcoQhPy2DQVSgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{ NWPJS2pzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlU5PzdpPkK0NVI2QDd5PD;hQi=>
SK-MEL-30 M4GxeGFxd3C2b4Ppd{Bie3OjeR?= Mk\2NVAxKHWP NVTzWmFGPDhiaILz NXeyfmYzUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT{1OTUxvM{CgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy|IHH0JFExOCC3TTDh[pRmeiB2ODDodpMh[nliQWDDMYxi[mWuZXSgZY5v\XirbjDWJIFv\CB5LVHBSEB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNicnXsZZRqfmVidH:gZ49vfHKxbB?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{NUi3O{c,OjRzMkW4O|c9N2F-
SK-MEL-30 NWKwTJJkSXCxcITvd4l{KGG|c3H5 M2DvR|UxKHWP MnHJOFghcHK| NXfBb45HUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDTT{1OTUxvM{CgZ4VtdHNiYYPz[ZN{\WRiYYOgZZBweHSxdHnjM45m[3KxdHnjJINmdGy|IHH0JFUxKHWPIHHmeIVzKDR6IHjyd{BjgSCDUFOtcIFj\WynZDDhco5mgGmwIG[gZY5lKDdvQVHEJJN1[WmwaX7nMYJie2WmIH\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyC{ZXzheIl3\SC2bzDjc451em:u MlLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMkW4O|coRjJ2MUK1PFc4RC:jPh?=
MNT1 NUPZTmFbSXCxcITvd4l{KGG|c3H5 MoXqNVAxKHWP NIHPT3A1QCCqcoO= NUXCbJE{UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNUnQyKGOnbHzzJIF{e2W|c3XkJIF{KGGyb4D0c5Rq[y:wZXPyc5Rq[yClZXzsd{BifCBzMECgeW0h[W[2ZYKgOFghcHK|IHL5JGFRSy2uYXLlcIVlKGGwbnX4bY4hXiCjbnSgO{1CSURic4ThbY5qdmdvYnHz[YQh\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzJJJmdGG2aY\lJJRwKGOxboTyc4w> NHLvbFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGyOVg4Pyd-MkSxNlU5Pzd:L3G+
MNT1 MnWxRZBweHSxc3nzJIF{e2G7 NUXCZ|JWPTBidV2= MUG0PEBpenN? M{e0PWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTV7UNUBk\WyuczDhd5Nme3OnZDDhd{BieG:ydH;0bYMwdmWlcn;0bYMh[2WubIOgZZQhPTBidV2gZYZ1\XJiNEigbJJ{KGK7IFHQR{1t[WKnbHXkJIFvdmW6aX6gWkBidmRiNz3BRWQhe3SjaX7pcocu[mG|ZXSg[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|IILlcIF1cX[nIITvJINwdnS{b3y= NWXrRZRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlU5PzdpPkK0NVI2QDd5PD;hQi=>
A2780 NHzDNWlEgXSxdH;4bYNqfHliYYPzZZk> MYe1JIRigXN? NU\MV|U5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigQ>? M134VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOFE5Lz5{NEmwNFQyQDxxYU6=
A2780/CP70 M1u2eWN6fG:2b4jpZ4l1gSCjc4PhfS=> Mn61OUBl[Xm| NIXhfZBEgXSxdH;4bYNqfHliYXfhbY5{fCCPTWKt[IVncWOrZX70JIh2dWGwIFGyO|gxN0OSN{CgZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WVDDhd5NigQ>? M4\5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOFE5Lz5{NEmwNFQyQDxxYU6=
GBM 047T M{S0cWFvfGm2dX3vdkBie3OjeR?= MWeyNEB2VQ>? NXzwNGJqOSC2bzCyJJdm\Wu| NWnMbVRyXHWvb4LpZ4ll[WxiZX\m[YN1KGmwIIDheIlmdnRiZHXybZZm\CCJQl2gNFQ4XCClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gcoV2em:|cHjldoUh\m:{bXH0bY9vKGG2IEKwJJVOKGGodHXyJFEhfG9iMjD3[YVseyCkeTCzSEB1fW2xcjDjcI9vd2enbnnjJIF{e2G7 MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN3NUWzNkc,OjZ|NUW1N|I9N2F-
GBM 464T M1rZRWFvfGm2dX3vdkBie3OjeR?= NYXGWIRpOjBidV2= MX:xJJRwKDJid3Xlb5M> M{DEWnR2dW:{aXPp[IFtKGWoZnXjeEBqdiCyYYTp[Y51KGSncnn2[YQhT0KPIES2OHQh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIH7leZJwe3CqZYLlJIZwem2jdHnvckBifCB{MDD1UUBi\nSncjCxJJRwKDJid3Xlb5Mh[nliM1SgeJVud3JiY3zvco9o\W6rYzDhd5NigQ>? NXPw[pJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOVU2OzJpPkK2N|U2PTN{PD;hQi=>
U87MG M4P1NWZ2dmO2aX;uJIF{e2G7 NHr4bm0{KGi{cx?= NFPoW4hKdmS3Y4Tpc44hd2ZiRF7BJIFtc3muYYTpc44hcW5iaIXtZY4hXTh5TVegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hVjdvTXXkS{Bnd3KvYYTpc44h[W[2ZYKgN{BpenNiYomgUGMuVVNxTWOgZY5idHm|aYO= M3\pU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NkG0OFE1Lz5{N{[xOFQyPDxxYU6=
U87MG M4DGT2FvfGm2dX3vdkBie3OjeR?= M4ThemFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJI9zfGixdH;wbYNidGy7IIjlco9oemGodHXkJIlvKEijcnzhckBvfWSnIH3veZNmKGK{YXnuJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDzcI94KHS3bX;yJIdzd3e2aDDheEA2OCC3bX;sM4toNCCrdjDh[I1qdmm|dHXy[YQhd26lZTDkZYltgSCob4KgOUBl[Xm| NUnnNohKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke2NVQ1OTRpPkK3OlE1PDF2PD;hQi=>
U87MG NWHSRZV[SW62aYT1cY9zKGG|c3H5 NH7jRXVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPFdOTyClZXzsd{BwenSqb4TvdIlk[WyueTD4[Y5w\3KjZoTl[EBqdiCKYYLsZY4hdnWmZTDtc5V{\SCkcnHpckBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDtc5V{\SC|dYL2bZZidCCjdDC1NEB2dW:uL3vnMEBqfiCjZH3pcol{fGW{ZXSgc45k\SCmYXnsfUBnd3JiNTDkZZl{ NFTR[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{[xOFQyPCd-Mke2NVQ1OTR:L3G+
MDCK MmH2R5l1d3SxeHnjbZR6KGG|c3H5 MXGyOEBpenN? MmT1R5l1d3SxeHnjbZR6KGGpYXnud5QhVUSFSzDj[YxteyCneIDy[ZN{cW6pIHPhdoJwdmmlIHHubJllemG|ZTC5JIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDt[YF{fXKnZDDh[pRmeiB5IHThfZMhfW6mZYKgco9zdW:6aXOgZ49v\Gm2aX;uJIJ6KG2ndHj5cIVv\SCkbIXlJJN1[WmwaX7nJIJie2WmIHPsc45w\2WwaXOgd5Vzfmm4YXygZZN{[Xl? Mo\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MkO4O|koRjJ5OEKzPFc6RC:jPh?=
MDCK MoHmR5l1d3SxeHnjbZR6KGG|c3H5 MUKyOEBpenN? MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBOTEONIHPlcIx{KGW6cILld5NqdmdiY3HyZo9vcWNiYX7ofYRz[XOnIEmgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGmwY4XiZZRm\CCob4KgNlQhcHK|IH3lZZN2emWmIHHmeIVzKDdiZHH5d{B2dmSncjDofZBwgGmlIHPvcoRqfGmxbjDifUBu\XSqeXzlcoUh[my3ZTDzeIFqdmmwZzDiZZNm\CClbH;uc4dmdmmlIIP1dpZqfmGuIHHzd4F6 NHTtSYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{iyN|g4QSd-Mke4NlM5Pzl:L3G+
NB-EBc1 MYDxTHRUKGG|c3H5 MnvrdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= M{juUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
C6 NEnJWINEgXSxdH;4bYNqfHliYYPzZZk> NVjkdWE3PCCmYYnz NVnlV5J7TUN3MDC9JFE3NjVizszN NYLl[Vh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
U87 NXfDN2JZS3m2b4TvfIlkcXS7IHHzd4F6 NH;Rflg4OiCqcoO= NWjESo85UUN3MDC9JFE6NjN6IN88US=> NHnLOnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw5OTBxJ{7DbGVOSkx:L3G+
SNB19 M1\COWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGD2d3M4KGSjeYO= MYDHTVUxKD1iM{WuO{DPxE1? M1;vSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFgyOC9pPlPoSW1DVDxxYU6=
SNB19 M13oO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUO3JIRigXN? MWLHTVUxKD1iNEWuOkDPxE1? MnixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMPFExNyd-Q3jFUWJNRC:jPh?=
U373 MXLGeY5kfGmxbjDhd5NigQ>? M{nndFExOCC3TR?= M1vDRlczKGi{cx?= M1\XSmlv\HWldHnvckBw\iCmb4XicIUhe3S{YX7k[YQhTE6DIHLy[YFsKGmwIHXtdJR6KH[nY4TvdkB1emGwc3\lZ5Rm\CCqdX3hckBWOzd|IHPlcIx{KGG|c3Xzd4VlKGG|IHnuZ5Jm[XOnIHnuJIdidW2jLViyRXghdGW4ZXygZZQhOTByIIXNJIFnfGW{IEeyJIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>? NUT6VHRSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNQDFyLze+R4hGVUKOPD;hQi=>
Glioma NV2ySIhVSW62aYT1cY9zKGG|c3H5 NIrvfYZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBJd22xIIPhdIlmdnNiKHj1cYFvMSCJbHnvcYEh[2WubIOgfIVvd2e{YX\0[YQhcW5idILhcpNo\W6rYzDtc5V{\SCjc4Pld5Nm\CCjczDtc5V{\SC|dYL2bZZidA>? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly4NVAwLz6FaFXNRmw9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856,TMZ
Smiles CN1C(=O)N2C=NC(=C2N=N1)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04610736 Not yet recruiting Drug: Temozolomide Oral Suspension Pediatric Cancer Orphelia Pharma|ClinSearch January 2021 Phase 1
NCT04514393 Not yet recruiting Drug: Methotrexate|Drug: Ibrutinib|Drug: Temozolomide Primary Central Nervous System Lymphoma|PCNSL|Non Hodgkin Lymphoma Huiqiang Huang|Guangdong 999 Brain Hospital|Nanfang Hospital of Southern Medical University|Xian-Janssen Pharmaceutical Ltd.|Sun Yat-sen University December 1 2020 Phase 2
NCT04238819 Recruiting Drug: Abemaciclib|Drug: Irinotecan|Drug: Temozolomide Relapsed Solid Tumor|Refractory Solid Tumor Eli Lilly and Company November 9 2020 Phase 1
NCT03796507 Not yet recruiting Drug: Temozolomide Glioma of Brain University of Rochester|National Institutes of Health (NIH) September 1 2020 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID